Latest Conference Articles

June 12th 2021, 7:47pm

European Hematology Association Congress

A study of treatment patterns in adult patients with mantle cell lymphoma revealed a discrepancy between actual patterns of care and recommendations based on clinical trials.

June 12th 2021, 6:18pm

European Hematology Association Congress

Compared to currently available therapies, treatment with axicabtagene ciloleucel induced substantial objective response rate, progression-free survival, time to next treatment and overall survival improvements in patients with relapsed/refractory follicular lymphoma.

June 12th 2021, 6:09pm

European Hematology Association Congress

The combination of naratuximab emtansine and rituximab yielded deep responses, and a duration of response that was not reached in patients with relapsed or refractory diffuse large B-cell lymphoma.

June 12th 2021, 4:26pm

European Hematology Association Congress

The addition of daratumumab to lenalidomide and dexamethasone continued to reduced the risk of death by 32% compared with Rd alone in patients with newly diagnosed multiple myeloma who are transplant ineligible after almost 5 years of follow-up.

June 12th 2021, 3:25pm

European Hematology Association Congress

Fixed-duration ibrutinib and venetoclax as a first-line treatment yielded superior progression-free survival compared with chlorambucil plus obinutuzumab in patients with chronic lymphocytic leukemia.

June 12th 2021, 2:42pm

European Hematology Association Congress

Rusfertide has been shown to be an effective option for patients with polycythemia vera in that it reverses iron deficiency, improves disease-related symptoms, and eliminates the need for therapeutic phlebotomy.

June 12th 2021, 2:35pm

European Hematology Association Congress

Daratumumab maintenance therapy yielded an increase in response following autologous stem cell transplant plus induction and consolidation therapy with bortezomib, thalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

June 12th 2021, 1:47pm

European Hematology Association Congress

In the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large b-cell lymphoma in the outpatient setting who are receiving the CAR T-cell therapies prior to failure on 2 prior lines of therapy.

June 12th 2021, 1:28pm

European Hematology Association Congress

The next-generation, selective BTK inhibitor acalabrutinib demonstrated noninferiority to ibrutinib in terms of progression-free survival in patients with previously treated chronic lymphocytic leukemia in the phase 3 ELEVATE-RR trial.

June 12th 2021, 1:01am

ASCO Annual Meeting

Aditya Bardia, MD, MPH, discusses ongoing research with amcenestrant and palbociclib in estrogen receptor–positive, HER2-negative advanced breast cancer.

June 12th 2021, 12:53am

ASCO Annual Meeting

Sarat Chandarlapaty, MD, PhD, highlights responses to amcenestrant and palbociclib in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer, as seen in the phase 1/2 AMEERA 1 trial.

June 12th 2021, 12:45am

ASCO Annual Meeting

Margaret von Mehren, MD, discusses outcomes with ribociclib and everolimus in dedifferentiated liposarcoma, as seen in the phase 2 SAR-096 trial.

June 11th 2021, 11:45pm

European Hematology Association Congress

Zanubrutinib continued to induce deep responses with acceptable tolerability in patients with relapsed/refractory chronic lymphocytic leukemia, including those with high-risk cytogenetics.

June 11th 2021, 11:14pm

European Hematology Association Congress

Axicabtagene ciloleucel demonstrated significant clinical activity with durable responses in patients with relapsed/refractory indolent non-Hodgkin lymphoma who experienced disease progression within 24 months from initiation of the first anti-CD20–containing chemotherapy, which is a high-risk clinical feature.

June 11th 2021, 10:56pm

Luspatercept-aamt achieved a 77.1% mean hemoglobin increase of 1.0 g/dL or higher from baseline over a continuous 12-week interval during weeks 13 to 24 in the absence of red blood cell transfusions vs 0% with placebo in patients with non-transfusion–dependent β-thalassemia.

June 11th 2021, 9:55pm

European Hematology Association Congress

Although cardiovascular health of patients with myeloproliferative neoplasms was relatively good, an estimated 11% to 22% of patients were not prescribed appropriate medications for management of comorbidities associated with thrombotic risk.

June 11th 2021, 9:49pm

European Hematology Association Congress

Time-to-next treatment and overall survival were improved in a real-world study evaluating patients who received rituximab maintenance after first-line treatment with bendamustine and rituximab or R-CHOP in patients with mantle cell lymphoma.

June 11th 2021, 9:42pm

European Hematology Association Congress

The fixed-dose combination of the BCL-2 inhibitor venetoclax and the humanized anti-CD20 monoclonal antibody obinutuzumab continued to confer a progression-free survival advantage over chlorambucil plus obinutuzumab for patients with previously untreated chronic lymphocytic leukemia.

June 11th 2021, 9:31pm

European Hematology Association Congress

Intensified induction therapy with daratumumab in addition to cyclophosphamide, bortezomib, lenalidomide, and dexamethasone and bortezomib-augmented autologous stem cell transplant yielded robust responses in patients with ultra¬ high–risk multiple myeloma or primary plasma cell leukemia

June 11th 2021, 9:02pm

European Hematology Association Congress

Patients with relapsed/refractory multiple myeloma who were treated with ciltacabtagene autoleucel experienced improved outcomes over those who received a conventional therapy